abraxas1 Antibody

What are the key considerations when selecting an ABRAXAS1 antibody for research applications?

When selecting an ABRAXAS1 antibody, researchers should consider several important factors. First, determine the specific application needs (Western blot, immunohistochemistry, flow cytometry, etc.) as antibody performance varies across applications. Second, evaluate the antibody's specificity for ABRAXAS1 by reviewing validation data and published citations. Third, consider the species reactivity needed for your experimental model; ABRAXAS1 antibodies are available with reactivity to human, mouse, rat, and other species including zebrafish, bovine, and chimpanzee . Fourth, determine whether you need a monoclonal or polyclonal antibody based on your experimental requirements for specificity versus epitope recognition. Finally, check if the antibody recognizes specific regions of ABRAXAS1, as some antibodies target the C-terminal region which contains the important phosphorylation sites that mediate BRCA1 interaction .

How do I verify the specificity of an ABRAXAS1 antibody for my research?

Verifying antibody specificity is a critical step in ensuring reliable experimental results. Start by performing a Western blot analysis using positive control samples (cell lines known to express ABRAXAS1) and negative controls (knockout cell lines or tissues where ABRAXAS1 is not expressed). The antibody should detect a band at approximately 46.7 kDa, corresponding to the molecular weight of ABRAXAS1 . Additionally, you can use siRNA or CRISPR-mediated knockdown of ABRAXAS1 to further confirm specificity by demonstrating reduced signal intensity. For immunostaining applications, include appropriate controls and verify nuclear localization, as ABRAXAS1 is predominantly a nuclear protein . Finally, consider using multiple antibodies targeting different epitopes of ABRAXAS1 to cross-validate your findings, particularly in novel or controversial research areas.

What are the key differences between monoclonal and polyclonal ABRAXAS1 antibodies in research applications?

Monoclonal and polyclonal ABRAXAS1 antibodies offer distinct advantages depending on your research needs. Monoclonal antibodies, developed from a single B-cell clone, recognize a single epitope on ABRAXAS1, providing high specificity and consistency between batches. They're particularly valuable for distinguishing between ABRAXAS1 isoforms or specific post-translational modifications . Polyclonal antibodies, derived from multiple B-cells, recognize multiple epitopes on ABRAXAS1, making them more robust to protein denaturation and potentially providing stronger signals in applications like Western blotting. This multi-epitope recognition can be advantageous for detecting ABRAXAS1 in fixed tissues or when protein conformation may be altered. For critical quantitative experiments, monoclonals typically offer better reproducibility, while polyclonals may provide greater sensitivity in applications where ABRAXAS1 expression is low. For studies involving ABRAXAS1's interaction with BRCA1, carefully consider epitope location, as antibodies targeting the C-terminal phosphorylation region might interfere with protein-protein interactions .

What are the optimal conditions for using ABRAXAS1 antibodies in Western blot analysis?

For optimal Western blot results with ABRAXAS1 antibodies, careful sample preparation and protocol optimization are essential. Begin by extracting nuclear proteins using appropriate buffer systems, as ABRAXAS1 is predominantly localized in the nucleus . For cell lysis, use buffers containing phosphatase inhibitors to preserve ABRAXAS1's phosphorylation state, particularly if studying BRCA1 interactions. Load 20-50 μg of total protein per lane and separate using 10-12% SDS-PAGE gels, which provide optimal resolution for the 46.7 kDa ABRAXAS1 protein. For transfer, semi-dry or wet transfer systems are both suitable, but wet transfer may provide better results for this nuclear protein. Use PVDF membranes for increased protein binding capacity and signal intensity. Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature, then incubate with primary ABRAXAS1 antibody at dilutions typically ranging from 1:500 to 1:2000 (specific dilutions should be optimized for each antibody) . For detection, both chemiluminescence and fluorescence-based secondary antibodies work well. When analyzing results, be aware that ABRAXAS1 may appear as multiple bands due to post-translational modifications, particularly phosphorylation events critical to its function in DNA damage response .

How can I optimize immunohistochemistry protocols for ABRAXAS1 detection in tissue samples?

Optimizing immunohistochemistry (IHC) for ABRAXAS1 requires attention to several key factors. For fixation, 10% neutral buffered formalin for 24-48 hours is recommended to preserve ABRAXAS1 antigenicity while maintaining tissue architecture. Antigen retrieval is critical; heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) for 15-20 minutes is typically effective for exposing ABRAXAS1 epitopes. Test both methods to determine optimal conditions for your specific antibody. Permeabilization with 0.1-0.3% Triton X-100 may improve nuclear staining of ABRAXAS1. For primary antibody incubation, dilutions between 1:100 and 1:500 are common starting points, but should be titrated for each antibody . Overnight incubation at 4°C often yields better results than shorter incubations. When developing signal, be aware that ABRAXAS1 exhibits nuclear localization with potential enrichment at DNA damage sites. For validation, incorporate positive controls (breast or ovarian tissue) and negative controls (antibody diluent only). When interpreting results, remember that ABRAXAS1 expression may vary in cancer tissues, particularly those with BRCA1 pathway alterations, making comparative analysis between normal and tumor tissues informative .

What are the best approaches for using ABRAXAS1 antibodies in immunoprecipitation studies to investigate protein-protein interactions?

Immunoprecipitation (IP) studies with ABRAXAS1 antibodies require careful consideration of complex protein interactions, particularly with BRCA1 and other components of the BRCA1-A complex. For cell lysis, use gentle non-denaturing buffers (e.g., 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40 or 0.5% Triton X-100) supplemented with protease and phosphatase inhibitors to preserve protein-protein interactions and post-translational modifications . Pre-clear lysates with protein A/G beads to reduce non-specific binding. For antibody binding, select ABRAXAS1 antibodies that don't target interaction domains, particularly the C-terminal phospho-S404/S406 region that mediates BRCA1 binding, unless specifically studying these interactions . Use 2-5 μg of antibody per 500 μg-1 mg of protein lysate, incubating overnight at 4°C with gentle rotation. After washing (at least 4-5 times), elute proteins under conditions appropriate for downstream applications. For studying DNA damage-induced interactions, consider treating cells with ionizing radiation (2-10 Gy) or etoposide before lysis, as these treatments enhance ABRAXAS1-BRCA1 interactions . To confirm specificity, include controls such as IgG-only IP and ABRAXAS1-depleted samples. Co-IP experiments can effectively demonstrate interactions with BRCA1, BARD1, RAP80, BRCC36, and other components of the DNA damage response machinery .

How does ABRAXAS1 function within the BRCA1-A complex in DNA damage response pathways?

ABRAXAS1 serves as a central scaffold protein in the BRCA1-A complex, playing a crucial role in DNA damage response signaling. After double-strand break (DSB) formation, the RNF8 and RNF168 E3 ubiquitin ligases generate ubiquitinated histone H2A (H2AK13/K15ub), which is recognized by the UIM domains of RAP80, a component of the BRCA1-A complex . ABRAXAS1 directly interacts with RAP80 and simultaneously binds to BRCA1 through its phosphorylated C-terminal S404/S406 residues, which dock with the BRCT domains of BRCA1 . This interaction is essential for recruitment of BRCA1 to DNA damage sites, as demonstrated by studies showing that ABRAXAS1 mutants defective in BRCA1 binding fail to properly localize BRCA1 to damage sites and compromise DNA repair efficiency . Within this complex, ABRAXAS1 also interacts with MERIT40 (NBA1) and BRCC36, the latter being a deubiquitinating enzyme that regulates the ubiquitin signals at damage sites. Through these coordinated interactions, ABRAXAS1 facilitates the assembly and stability of the BRCA1-A complex at DNA damage sites, allowing BRCA1 to execute its functions in DNA repair pathway choice and checkpoint activation . Research using Abraxas knockout mouse models has demonstrated that loss of ABRAXAS1 leads to defects in DNA repair, accumulation of chromosomal aberrations, and predisposition to cancer, highlighting its essential role in maintaining genomic stability .

What experimental approaches are most effective for studying ABRAXAS1's role in homologous recombination repair?

Studying ABRAXAS1's role in homologous recombination (HR) repair requires a multi-faceted experimental approach. Start with ABRAXAS1 knockout or knockdown systems using CRISPR-Cas9 or siRNA technologies, respectively. In these systems, assess HR efficiency using reporter assays such as the DR-GFP assay, which measures HR-mediated repair of I-SceI-induced DSBs . Complementation experiments with wild-type and mutant ABRAXAS1 (particularly S404A, which disrupts BRCA1 interaction) can distinguish which domains are essential for HR function . To visualize ABRAXAS1's role in the HR process, perform immunofluorescence microscopy after inducing DNA damage with ionizing radiation (2-10 Gy) or radiomimetic drugs, and quantify colocalization with γH2AX (marking DSBs) and recruitment of HR factors like RAD51. Analysis should include kinetics of focus formation and resolution . Proximity ligation assays can detect in situ interactions between ABRAXAS1 and other HR proteins. Functional HR assessment can be performed using cell survival assays after treatment with PARP inhibitors (e.g., olaparib), which are selectively toxic to HR-deficient cells . Comet assays under neutral conditions can measure DSB repair efficiency in ABRAXAS1-deficient versus proficient cells . Finally, chromatin immunoprecipitation (ChIP) can be used to measure recruitment of ABRAXAS1 and associated proteins to specific DSB sites induced by systems like I-SceI or CRISPR-Cas9.

How can researchers effectively measure the impact of ABRAXAS1 deficiency on genomic stability?

Measuring the impact of ABRAXAS1 deficiency on genomic stability requires a comprehensive approach combining cytogenetic, molecular, and functional assays. Metaphase spread analysis is a powerful technique for visualizing chromosomal abnormalities; research has shown that ABRAXAS1-deficient cells exhibit approximately 3-fold increase in spontaneous single chromatid breaks compared to wild-type cells, with even more severe phenotypes following ionizing radiation, including multiple breaks, chromosomal fusions, and radial structures . Micronucleus assays provide a high-throughput method to quantify chromosomal fragmentation, with ABRAXAS1-deficient cells showing increased nuclear fragmentation and micronuclei formation . DNA damage persistence can be measured using neutral comet assays, which revealed repair deficiencies in ABRAXAS1-knockout cells . For molecular markers of genomic instability, phospho-H2AX (γH2AX) foci analysis by immunofluorescence microscopy can quantify unrepaired DNA breaks over time. Sister chromatid exchange (SCE) rates typically increase in cells with compromised genomic stability. Long-term consequences of ABRAXAS1 deficiency can be assessed through cell transformation assays, showing increased spontaneous transformation rates, and in vivo tumorigenesis studies using ABRAXAS1-knockout mouse models, which demonstrated predisposition to multiple cancer types . When performing these analyses, always include complementation experiments with wild-type ABRAXAS1 and separation-of-function mutants (particularly S404A, which disrupts BRCA1 binding) to establish causality and elucidate mechanism .

What is the significance of ABRAXAS1 mutations in breast and ovarian cancer research?

ABRAXAS1 mutations have emerged as important factors in breast and ovarian cancer pathogenesis, particularly in the context of BRCA1 pathway disruption. Research has identified that ABRAXAS1 functions as a tumor suppressor gene, with its deficiency leading to genomic instability and predisposition to cancer development . Mutations in ABRAXAS1, particularly those affecting the BRCA1-binding region (such as the phosphorylation sites S404/S406), compromise DNA repair efficiency and chromosomal stability . Clinical studies have identified germline mutations in ABRAXAS1 in patients with early-onset breast cancer and familial breast cancer cases without BRCA1/2 mutations, suggesting ABRAXAS1 may be a moderate-penetrance breast cancer susceptibility gene . The mechanistic significance of these mutations lies in their disruption of the BRCA1-A complex formation, which impairs proper localization of BRCA1 to DNA damage sites and subsequent homologous recombination repair functions. When studying ABRAXAS1 mutations in cancer research, it's important to distinguish between mutations that affect protein stability, those that disrupt BRCA1 binding, and those that interfere with other protein interactions within the BRCA1-A complex . Functional characterization of these mutations using the experimental approaches discussed in previous questions is essential for understanding their pathogenic significance. Importantly, ABRAXAS1-deficient tumors may share features with BRCA1-deficient tumors, including potential sensitivity to PARP inhibitors, making ABRAXAS1 status a potential biomarker for therapeutic stratification .

How can ABRAXAS1 antibodies be used to assess BRCA1 pathway functionality in tumor samples?

ABRAXAS1 antibodies provide valuable tools for assessing BRCA1 pathway functionality in tumor samples through multiple approaches. Immunohistochemistry (IHC) using validated ABRAXAS1 antibodies can evaluate protein expression levels and subcellular localization in formalin-fixed paraffin-embedded (FFPE) tumor tissues . Decreased nuclear ABRAXAS1 expression may indicate pathway disruption, while mislocalization could suggest functional abnormalities. For more mechanistic insights, dual immunofluorescence staining for ABRAXAS1 and BRCA1 can reveal colocalization patterns and potential defects in complex formation. In fresh tumor samples, co-immunoprecipitation using ABRAXAS1 antibodies followed by BRCA1 detection can directly assess the ABRAXAS1-BRCA1 interaction status . To evaluate functional activity, immunofluorescence detection of radiation-induced ABRAXAS1 and BRCA1 foci formation in ex vivo cultured tumor cells can reveal deficiencies in the DNA damage response. Proximity ligation assays (PLA) offer an alternative approach for detecting ABRAXAS1-BRCA1 interactions in situ in tissue sections. For comprehensive pathway assessment, combine ABRAXAS1 analysis with evaluation of other BRCA1-A complex components (RAP80, MERIT40, BRCC36) and downstream HR markers (RAD51 foci). This multi-protein approach can provide a more complete picture of pathway functionality than single-protein analysis. When interpreting results, consider that post-translational modifications, particularly phosphorylation at S404/S406 of ABRAXAS1, are crucial for BRCA1 interaction, so phospho-specific antibodies may provide additional insights into pathway activity .

What are the methodological considerations when analyzing ABRAXAS1 expression and localization in clinical cancer specimens?

Analyzing ABRAXAS1 in clinical cancer specimens requires addressing several methodological challenges. For FFPE tissues, optimal antigen retrieval is critical; test both citrate (pH 6.0) and EDTA-based (pH 9.0) buffers, as ABRAXAS1 epitope accessibility may vary between antibodies and fixation conditions . When selecting antibodies, prioritize those validated specifically for IHC applications with documented specificity in positive and negative control tissues . Establish proper scoring systems for ABRAXAS1 expression, considering both intensity (0-3+) and percentage of positive cells, with attention to subcellular localization patterns, as ABRAXAS1 should primarily show nuclear staining . Include internal positive controls (normal breast epithelium or lymphocytes) within each specimen to ensure staining validity. For phospho-ABRAXAS1 detection, tissue fixation time is critical—lengthy formalin fixation can diminish phospho-epitope detection. When analyzing results, remember that ABRAXAS1 expression may be heterogeneous within tumors, necessitating evaluation of multiple regions. Multiplex immunofluorescence combining ABRAXAS1 with other BRCA1 pathway proteins provides valuable contextual information about pathway status. For quantitative analysis, digital pathology platforms with nuclear algorithm scripts can improve objectivity and reproducibility. In tissue microarray studies, include multiple cores per tumor to account for intratumoral heterogeneity. Finally, integrate ABRAXAS1 protein data with genomic findings (mutations, copy number alterations) and clinical outcomes for comprehensive analysis of ABRAXAS1's significance in cancer biology .

How can researchers distinguish between the functions of ABRAXAS1 and ABRAXAS2 (ABRO1) in experimental systems?

Distinguishing between ABRAXAS1 and ABRAXAS2 (ABRO1) functions requires careful experimental design due to their structural similarities but distinct biological roles. When selecting antibodies, ensure absolute specificity by verifying they don't cross-react with the paralog—validate using knockout cells for each protein separately . Design siRNAs or CRISPR guide RNAs targeting unique regions to avoid off-target effects on the paralog. For localization studies, immunofluorescence microscopy can reveal their different subcellular distributions: ABRAXAS1 is predominantly nuclear and forms IR-induced foci at DNA damage sites, while ABRAXAS2/ABRO1 localizes primarily to the cytoplasm with distinct distribution patterns . To distinguish their protein interaction networks, perform immunoprecipitation followed by mass spectrometry—ABRAXAS1 primarily interacts with BRCA1 and BRCA1-A complex components, whereas ABRAXAS2/ABRO1 associates with BRCC36 in the cytoplasmic BRISC complex . Functional separation can be achieved through complementation experiments in double-knockout cell lines, reintroducing either protein to determine which functions are rescued. Domain swap experiments, where unique regions of each protein are exchanged, can identify specific functional domains. For physiological studies, use cell type-specific knockouts, as ABRAXAS1 functions are more prominent in homologous recombination-proficient cells, while ABRAXAS2/ABRO1's roles may be more evident in specific immune contexts. When analyzing results, remember that while both proteins share the ability to bind BRCC36 deubiquitinating enzyme, their distinct localizations and complex formations direct this activity to different cellular compartments and ubiquitin substrates.

What are the technical challenges in studying ABRAXAS1 phosphorylation states and how can they be overcome?

Studying ABRAXAS1 phosphorylation presents several technical challenges. The dynamic and often transient nature of phosphorylation events, particularly those induced by DNA damage, requires careful timing in experimental designs. Collect samples at multiple time points after DNA damage induction (typically 15 minutes to 8 hours post-irradiation) to capture the full phosphorylation kinetics . During sample preparation, rapid dephosphorylation by cellular phosphatases can be prevented by incorporating phosphatase inhibitor cocktails in all buffers and maintaining samples at 4°C throughout processing. For detection, phospho-specific antibodies targeting key sites (particularly S404/S406) are essential but may have lower affinity than pan-ABRAXAS1 antibodies; optimize antibody concentrations and incubation conditions accordingly . When phospho-specific antibodies are unavailable, alternative approaches include Phos-tag gel electrophoresis, which can separate phosphorylated from non-phosphorylated ABRAXAS1 based on mobility shifts. Mass spectrometry offers the most comprehensive analysis of phosphorylation sites, but requires enrichment strategies such as titanium dioxide (TiO2) chromatography or immunoprecipitation with phospho-specific antibodies to detect low-abundance phosphopeptides. For functional studies, generate phospho-mimetic (S to D/E) and phospho-deficient (S to A) mutants of key sites to simulate constitutively phosphorylated or unphosphorylated states . When interpreting results, consider that different phosphorylation sites may have distinct functions—S404/S406 mediates BRCA1 interaction, while other sites may regulate protein stability or other interactions .

How can emerging proteomic and imaging technologies be applied to advance ABRAXAS1 research in the context of DNA repair dynamics?

Emerging technologies are transforming ABRAXAS1 research in DNA repair contexts. Proximity-dependent labeling techniques like BioID or TurboID, where ABRAXAS1 is fused to a biotin ligase, can map its protein interaction network directly within living cells, revealing transient or weak interactions missed by traditional co-immunoprecipitation . These approaches can identify damage-specific interactors by comparing profiles before and after irradiation. CRISPR-based screening combined with high-content imaging enables systematic identification of genes affecting ABRAXAS1 localization or function. For high-resolution imaging, super-resolution microscopy techniques (STORM, PALM, SIM) can visualize ABRAXAS1 within repair foci at 20-50 nm resolution, revealing spatial organization relative to other repair factors . Live-cell imaging with fluorescently-tagged ABRAXAS1 variants allows real-time tracking of recruitment kinetics and protein dynamics at damage sites. For studying ABRAXAS1 in the chromatin context, CUT&RUN or CUT&Tag provide higher resolution than traditional ChIP for mapping ABRAXAS1 localization relative to damage sites. Single-cell proteomics can reveal cell-to-cell variability in ABRAXAS1 expression and phosphorylation states within heterogeneous tumor populations. Mass spectrometry-based interactomics with quantitative SILAC or TMT labeling can identify damage-induced changes in the ABRAXAS1 interactome . For clinical applications, highly multiplexed imaging technologies like CODEX or Imaging Mass Cytometry allow simultaneous visualization of ABRAXAS1 with dozens of other proteins in tissue sections, enabling comprehensive pathway analysis in the spatial context of the tumor microenvironment .